Health Insights, LLC
MD, MS | Physician-Scientist | Healthcare Strategist
Doximity · Harvard / Mass General Brigham · Boston, MA & New York, NY
Bridging cutting-edge medicine, national health policy,
and data-driven strategy to transform healthcare.
About
Dr. Kamal Menghrajani is a board-certified hematologist and medical oncologist whose career spans the frontiers of academic medicine, federal health policy, and translational science. Trained at the University of North Carolina, University of Michigan, and Memorial Sloan Kettering Cancer Center, she built her clinical expertise in leukemia, clonal hematopoiesis, and genomics-driven oncology.
As a faculty member on MSK's Leukemia Service, Dr. Menghrajani pursued NIH- and ASCO-funded research at the intersection of computational biology and clinical care — developing predictive models that are reshaping how clinicians understand cancer risk.
In 2023, she was selected as a White House Fellow — the first oncologist to serve in that role — where she served as the oncologist for the Cancer Moonshot initiative and as a physician on the Health Outcomes team under the Office of Science and Technology Policy (OSTP). In this role, she shaped federal strategy on cell and gene therapy, AI in healthcare, and health equity.
Dr. Menghrajani currently serves as the inaugural Medical Director for AI at Doximity — the nation's largest professional network for physicians — while continuing to practice oncology at Harvard / Mass General Brigham in Boston. In this dual role, she is shaping how artificial intelligence is developed, evaluated, and responsibly deployed across clinical medicine.
Through Health Insights, LLC, she offers strategic consulting to life sciences companies, health systems, and policy organizations seeking expert guidance at the intersection of oncology, data science, and health policy.
Areas of Expertise
Deep clinical and research expertise in leukemia, clonal hematopoiesis, and genomic oncology. Consulting on clinical development, rare disease strategy, and evidence generation for hematologic malignancies.
First-hand experience shaping federal health strategy through the White House Cancer Moonshot and OSTP. Advisory services on regulatory navigation, reimbursement innovation, and legislative engagement.
Expertise in machine learning applications for clinical decision support, biomarker discovery, and computational biology. Guiding responsible AI integration across health systems and life sciences organizations.
Biostatistics training and oncology trial experience informing protocol design, endpoint selection, adaptive trial architecture, and regulatory submission strategy from IND through approval.
Policy and clinical perspective on the evolving CGT landscape — spanning CAR-T, gene editing, and next-generation platforms. Strategic guidance on development pathways, access, and reimbursement frameworks.
Committed to reducing disparities in cancer outcomes and expanding access to precision medicine globally. Consulting on health equity strategy, global trial access, and population health initiatives.
Recognition
The first oncologist ever selected as a White House Fellow. Served as oncologist for the Cancer Moonshot and physician on the Health Outcomes team; appointed Assistant Director at the Office of Science and Technology Policy (OSTP).
Recipient of a prestigious NIH K12 Career Development Award supporting translational research in clonal hematopoiesis, genomics, and computational oncology at Memorial Sloan Kettering Cancer Center.
Recognized by the American Society of Clinical Oncology for outstanding early-career research contributions advancing the understanding and treatment of hematologic malignancies.
Invited speaker at the world's largest biotechnology industry conference — addressing AI in oncology, cell and gene therapy policy, and the future of cancer care innovation.
Get in Touch
Whether you're a life sciences company, health system, investor, or policy organization, Health Insights, LLC brings physician-scientist rigor and White House policy experience to your most complex strategic challenges.
Engagements include advisory board service, strategic consulting, speaking, expert testimony, and research collaboration.